Please assess the completion status of the following clinical trial:

Trial Title: Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Infants who meet all of the following criteria are eligible for the study:~* Mother known to be HIV-1-infected prior to labor or identified at the time of labor or \<48 hours postpartum. HIV-1 infection for the purposes of enrollment into this study is defined as: (a) Single positive HIV-1 rapid test in mother or her infant; or (b) Historical documentation of a positive HIV-1 diagnostic test confirmed by repeat diagnostic testing for HIV-1 according to country guidelines in mother (written documentation of test results must be present in the medical record).~* Maternal written informed consent for study participation.~* Mother has not received any antiretroviral therapy during the current pregnancy prior to the onset of labor and delivery; women may have received intravenous or oral ZDV during labor. Women may have received any antiretroviral therapy in previous pregnancies for prevention of vertical HIV-1 transmission.~* Infant is \<48 hours old. Infant may have received up to 48 hours of ZDV as standard care before study enrollment.~Exclusion Criteria:~Infants who meet any of the following criteria will be excluded from the study:~* Extreme prematurity (\< 32 weeks of gestation).~* Birth weight \<1500 grams.~* Presence of life-threatening conditions.~* Inability to take oral medication throughout the first 48 hours of life (must be able to receive oral medication by age 48 hours).~* Maternal inability to provide informed consent because of a lack of a conscious state, psychiatric conditions, or language barriers.~* Mother received any antiretroviral therapy during labor and delivery other than intravenous or oral ZDV.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 2 Days
- Healthy Volunteers: t

Study Arms:
- A (Type: EXPERIMENTAL): Standard of care ( Zidovudine only)
- B (Type: EXPERIMENTAL): Standard of care (Zidovudine) plus Nevirapine
- C (Type: EXPERIMENTAL): Standard of Care (Zidovudine) plus 2 weeks of Epivir and Nelfinavir

Based on this trial design, predict the completion outcome and termination type (if applicable).